Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCH Envoy Medical	$1.69 +4.0%	$1.53	$1.21 ▼ $3.99	$35.73M	2.22	81,484 shs	9,650 shs
LUCD Lucid Diagnostics	$1.16 +6.0%	$1.24	$0.72 ▼ $1.80	$124.96M	1.23	701,956 shs	591,655 shs
MGRM Monogram Orthopaedics	$5.75 -2.7%	$2.95	$1.92 ▼ $6.02	$205.75M	0.59	311,861 shs	272,363 shs
OBIO Orchestra BioMed	$3.16 +0.3%	$2.98	$2.37 ▼ $8.87	$121.80M	0.61	180,263 shs	66,545 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCH Envoy Medical	-1.22%	+6.58%	+18.25%	+20.90%	-28.95%
LUCD Lucid Diagnostics	-6.84%	-2.68%	-13.49%	-9.92%	+24.61%
MGRM Monogram Orthopaedics	+0.17%	+79.09%	+111.07%	+118.89%	+161.50%
OBIO Orchestra BioMed	+7.88%	+5.70%	-6.80%	+10.53%	-62.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COCH Envoy Medical	2.6871 of 5 stars	3.5	2.0	3.1	3.3	0.0
LUCD Lucid Diagnostics	2.5931 of 5 stars	3.6	2.0	2.9	1.7	0.6
MGRM Monogram Orthopaedics	1.0437 of 5 stars	1.8	2.0	2.5	1.7	0.6
OBIO Orchestra BioMed	2.9189 of 5 stars	3.6	5.0	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COCH Envoy Medical	3.00	Buy	$9.25	448.96% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.55	207.36% Upside
MGRM Monogram Orthopaedics	3.50	Strong Buy	$5.40	-6.09% Downside
OBIO Orchestra BioMed	3.20	Buy	$14.20	349.37% Upside

Current Analyst Ratings Breakdown

Latest COCH, MGRM, LUCD, and OBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/27/2025	COCH Envoy Medical	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.25 ➝ $9.50
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	COCH Envoy Medical	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $9.25
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COCH Envoy Medical	$220K	163.37	N/A	N/A	($0.88) per share	-1.91
LUCD Lucid Diagnostics	$4.17M	29.94	N/A	N/A	($0.78) per share	-1.48
MGRM Monogram Orthopaedics	$370K	554.64	N/A	N/A	$0.42 per share	13.69
OBIO Orchestra BioMed	$2.89M	41.95	N/A	N/A	$0.87 per share	3.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COCH Envoy Medical	-$20.80M	-$1.38	N/A	N/A	N/A	-10,656.13%	N/A	-237.44%	8/11/2025 (Estimated)
LUCD Lucid Diagnostics	-$45.53M	-$1.34	N/A	N/A	N/A	-1,699.86%	N/A	-124.27%	8/11/2025 (Estimated)
MGRM Monogram Orthopaedics	-$16.33M	-$0.45	N/A	N/A	N/A	N/A	-115.71%	-92.75%	8/13/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A

Latest COCH, MGRM, LUCD, and OBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	MGRM Monogram Orthopaedics	-$0.11	N/A	N/A	N/A	N/A	N/A
8/11/2025	N/A	COCH Envoy Medical	-$0.30	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	LUCD Lucid Diagnostics	-$0.09	N/A	N/A	N/A	$1.15 million	N/A
5/14/2025	Q1 2025	MGRM Monogram Orthopaedics	-$0.12	-$0.10	+$0.02	-$0.10	N/A	N/A
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COCH Envoy Medical	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
MGRM Monogram Orthopaedics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COCH Envoy Medical	N/A	1.09	0.88
LUCD Lucid Diagnostics	N/A	0.75	0.74
MGRM Monogram Orthopaedics	N/A	7.00	7.00
OBIO Orchestra BioMed	0.85	3.35	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COCH Envoy Medical	8.59%
LUCD Lucid Diagnostics	74.01%
MGRM Monogram Orthopaedics	0.45%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
COCH Envoy Medical	58.90%
LUCD Lucid Diagnostics	6.80%
MGRM Monogram Orthopaedics	28.10%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COCH Envoy Medical	34	21.33 million	8.77 million	Not Optionable
LUCD Lucid Diagnostics	70	108.19 million	100.83 million	No Data
MGRM Monogram Orthopaedics	28	35.69 million	25.66 million	Not Optionable
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable

COCH, MGRM, LUCD, and OBIO Headlines

Recent News About These Companies

Analysts Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Price Target at $14.20

July 15 at 2:35 AM | americanbankingnews.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Buy" by Brokerages

July 12, 2025 | marketbeat.com

Orchestra BioMed (NASDAQ:OBIO) Trading Up 1.7% - Here's What Happened

July 10, 2025 | marketbeat.com

Hedge funds owners may take dramatic actions as Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) recent 14% drop adds to one-year losses

July 2, 2025 | finance.yahoo.com

Orchestra BioMed Confirms Director Elections and Auditor

June 24, 2025 | tipranks.com

Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 Meeting

June 20, 2025 | nasdaq.com

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting

June 18, 2025 | msn.com

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

June 18, 2025 | globenewswire.com

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025 | seekingalpha.com

Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

May 14, 2025 | seekingalpha.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025 | globenewswire.com

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation

May 11, 2025 | msn.com

Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents

May 9, 2025 | nasdaq.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%

May 9, 2025 | aaii.comA

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 8, 2025 | finance.yahoo.com

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 5, 2025 | zacks.com

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025 | msn.com

Orchestra BioMed to Present at Jefferies Global Healthcare Conference

May 1, 2025 | msn.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%

May 1, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCH, MGRM, LUCD, and OBIO Company Descriptions

Envoy Medical NASDAQ:COCH

$1.68 +0.07 (+4.01%)

As of 12:39 PM Eastern

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Lucid Diagnostics NASDAQ:LUCD

$1.16 +0.07 (+5.96%)

As of 12:39 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Monogram Orthopaedics NASDAQ:MGRM

$5.75 -0.16 (-2.71%)

As of 12:39 PM Eastern

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.

Orchestra BioMed NASDAQ:OBIO

$3.16 +0.01 (+0.32%)

As of 12:38 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time